Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Eur J Cancer Care (Engl) ; 21(4): 485-92, 2012 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-22211832

RESUMO

The objective of this study is to investigate if changes in cognitive functions can be recognised in patients undergoing chemotherapy for breast cancer. Forty women with breast cancer and without depression underwent cognitive evaluation before and after 6 months of chemotherapy; emotional evaluation was performed before and after 1, 3 and 6 months of chemotherapy. Self-reported cognitive deficit evaluation was included. Global cognitive functioning before starting chemotherapy was good. After 6 months of treatment there was a significant decline in some cognitive functions, particularly involving the attention subdomain. Objective cognitive deficit resulted independent from the emotional status. On the contrary, self-perceived mental dysfunction was unrelated to the objective cognitive decline, but it was associated with depression and anxiety. Breast cancer chemotherapy can induce domain-specific cognitive dysfunction. Patients' self-perception of mental decline is unrelated to objective cognitive deficit. Breast cancer patients negatively judge their cognitive performances if they have a negative emotional functioning.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Neoplasias da Mama/tratamento farmacológico , Transtornos Cognitivos/induzido quimicamente , Adulto , Idoso , Cognição/efeitos dos fármacos , Feminino , Humanos , Pessoa de Meia-Idade , Testes Neuropsicológicos , Estudos Prospectivos
2.
Ital J Biochem ; 38(2): 75-82, 1989.
Artigo em Inglês | MEDLINE | ID: mdl-2745038

RESUMO

Prolonged treatment with caffeine promotes in rats an increase of liver ornithine carbamyltransferase activity (14-day treatment). In contrast, arginase activity is already reduced in brain and kidney after 10 days, and in the liver much later (17 days). Ornithine transaminase activity was increased in both liver and kidney, while in the brain it was reduced (17 days). Ornithine decarboxylase activity showed only minor modifications in kidney, while it was unchanged in brain. Of the polyamines, only spermidine was significantly modified, being increased in brain, decreased in liver and kidney. Although these results do not explain the mechanism of the modification of brain arginine and ornithine concentration promoted by caffeine, they point to further marked effects, i.e. on OAT activity and on spermidine concentration, which could have a relevant metabolic role.


Assuntos
Encéfalo/efeitos dos fármacos , Cafeína/farmacologia , Rim/efeitos dos fármacos , Fígado/efeitos dos fármacos , Ornitina/metabolismo , Adenosilmetionina Descarboxilase/metabolismo , Animais , Arginase/metabolismo , Encéfalo/metabolismo , Rim/metabolismo , Fígado/metabolismo , Masculino , Ornitina Carbamoiltransferase/metabolismo , Ornitina-Oxo-Ácido Transaminase/metabolismo , Putrescina/metabolismo , Ratos , Espermidina/metabolismo , Espermina/metabolismo , Ácido gama-Aminobutírico/metabolismo
3.
New Microbiol ; 27(1): 17-20, 2004 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-14964401

RESUMO

A survey network for congenital toxoplasmosis (TOXO-NET) was set up in December 1996 in Piedmont (Italy). Participants were asked to classify the infections in pregnant mothers and newborns by the criteria of the European Network on Congenital Toxoplasmosis published by Lebech in 1996. Because the IgG Avidity test is largely employed as a 2nd level test in toxoplasmosis diagnosis and it could be helpful to date infection, the co-ordinators of TOXO-NET suggested including it in the "case definition" of "probable" infection and "unlikely" infection. 117 cases of toxoplasmosis in pregnancy divided into the risk categories under Lebech's criteria were re-examined using the "new" case definitions. 77 out of 117 (65.8%) Toxoplasma gondii infections during pregnancy could be defined with only one serum sample using the IgG Avidity test. The IgG Avidity test proved a useful method to classify the Toxoplasma gondii infections in pregnancy, especially when we had only one serum sample.


Assuntos
Anticorpos Antiprotozoários/imunologia , Afinidade de Anticorpos , Imunoglobulina G/imunologia , Complicações Parasitárias na Gravidez/diagnóstico , Toxoplasma/imunologia , Toxoplasmose/diagnóstico , Animais , Feminino , Humanos , Gravidez , Complicações Parasitárias na Gravidez/parasitologia , Kit de Reagentes para Diagnóstico , Toxoplasmose/parasitologia
4.
Lett Appl Microbiol ; 47(4): 309-14, 2008 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-19241525

RESUMO

AIMS: This study compared the in vitro activity of telithromycin with that of azithromycin against 438 Streptococcus pyogenes and 198 Streptococcus pneumoniae, isolated over the period 2005-2007 from specimens of different human origin obtained in three Piemonte Region's hospitals. METHODS AND RESULTS: The determination of antimicrobial activity was evaluated by the microdilution broth method and the erythromycin-resistant (Ery-R) phenotypes by the triple-disc test. Exactly 78.8% of S. pyogenes and 69.2% of S. pneumoniae were erythromycin-susceptible (Ery-S). Concerning S. pyogenes, telithromycin was active against M and inducible MLS(B), subtype-C, phenotypes but not against constitutive MLS(B) strains. Telithromycin acted well against all S. pneumoniae, irrespective of their mechanism of macrolide-resistance. On the contrary, the Ery-R isolates, both S. pyogenes and S. pneumoniae, were resistant to azithromycin. CONCLUSIONS: Our results indicate that macrolide resistance in streptococci still persist in northwest Italy (21.2% of S. pyogenes and 308% of S. pneumoniae) and that telithromycin is confirmed as being extremely active even against recent clinical Ery-R streptococcal isolates. SIGNIFICANCE AND IMPACT OF THE STUDY: The present study emphasizes that an active surveillance of the phenotype distribution and antibacterial resistance in streptococci is essential in guiding the effective use of empirical treatment option for streptococcal infections, also at regional level.


Assuntos
Antibacterianos/farmacologia , Azitromicina/farmacologia , Cetolídeos/farmacologia , Streptococcus pneumoniae/efeitos dos fármacos , Streptococcus pyogenes/efeitos dos fármacos , Adulto , Criança , Farmacorresistência Bacteriana , Eritromicina/farmacologia , Humanos , Itália , Testes de Sensibilidade Microbiana , Infecções Estreptocócicas/microbiologia , Streptococcus pneumoniae/isolamento & purificação
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA